Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$4.15 - $8.37 $63,246 - $127,558
15,240 Added 9.29%
179,225 $808,000
Q1 2022

May 13, 2022

SELL
$5.91 - $14.38 $136,615 - $332,408
-23,116 Reduced 12.35%
163,985 $1.21 Million
Q4 2021

Feb 11, 2022

BUY
$5.21 - $8.61 $282,137 - $466,257
54,153 Added 40.73%
187,101 $1.21 Million
Q3 2021

Nov 10, 2021

BUY
$4.45 - $10.63 $66,812 - $159,598
15,014 Added 12.73%
132,948 $774,000
Q2 2021

Aug 16, 2021

SELL
$8.11 - $11.11 $469,204 - $642,769
-57,855 Reduced 32.91%
117,934 $1.22 Million
Q1 2021

May 13, 2021

SELL
$9.85 - $17.69 $1.29 Million - $2.32 Million
-131,314 Reduced 42.76%
175,789 $1.85 Million
Q4 2020

Feb 16, 2021

BUY
$14.15 - $17.19 $1.59 Million - $1.93 Million
112,286 Added 57.64%
307,103 $4.75 Million
Q3 2020

Nov 13, 2020

SELL
$14.14 - $19.71 $66,882 - $93,228
-4,730 Reduced 2.37%
194,817 $2.84 Million
Q2 2020

Aug 14, 2020

BUY
$16.6 - $25.25 $1.73 Million - $2.63 Million
104,175 Added 109.23%
199,547 $3.78 Million
Q1 2020

May 14, 2020

BUY
$14.38 - $27.72 $207,316 - $399,639
14,417 Added 17.81%
95,372 $1.83 Million
Q4 2019

Feb 13, 2020

BUY
$9.23 - $19.67 $747,214 - $1.59 Million
80,955 New
80,955 $1.55 Million
Q1 2019

May 13, 2019

SELL
$4.12 - $10.25 $454,839 - $1.13 Million
-110,398 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$8.2 - $16.95 $14,718 - $30,425
1,795 Added 1.65%
110,398 $1.03 Million
Q3 2018

Nov 13, 2018

BUY
$17.03 - $21.18 $166,638 - $207,246
9,785 Added 9.9%
108,603 $1.85 Million
Q2 2018

Aug 13, 2018

BUY
$12.0 - $19.88 $1.19 Million - $1.96 Million
98,818 New
98,818 $1.68 Million

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $55.9M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.